Solos Endoscopy, Inc. Receives Purchase Order from Leading San Diego Healthcare Provider

Solos Endoscopy, Inc. Receives Purchase Order from Leading San Diego
Healthcare Provider

BOSTON, March 24 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets:
SNDY) is pleased to announce that the Company has received a purchase order
for the MammoView(TM) line of surgical endoscopy instruments from Sharp
Healthcare, one of San Diego's leading healthcare networks. Sharp Healthcare
has 14,000 employees and 2600 affiliated doctors. Sharp was named the best
integrated healthcare network in the State of California, where, in 2007, it
won the Malcolm Baldridge Quality Award.

Sharp HealthCare is a not-for-profit integrated regional health care delivery
system based in San Diego, California. Sharp includes four acute-care
hospitals, three specialty hospitals and two medical groups, plus a full
spectrum of other facilities and services. As San Diego's health care leader,
Sharp has an unwavering commitment to excellence and passion for caring.

"We are proud to be a supplier to such a prestigious healthcare provider. The
Sharp Healthcare Network has been serving the San Diego community for over 50
years and we look forward to creating a long term relationship with the entire
Sharp organization," stated Bob Segersten, President of Solos Endoscopy, Inc.

For more information on Sharp Healthcare, please visit
http://www.sharp.com/en/about/.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to
develop and market breakthrough technology, applications, medical devices and
procedural techniques for the screening, diagnosis, treatment and management
of medical conditions. Backed by technical support, Solos' sales team can help
make the right buying decisions for the hospital, surgery center, or physician
office. Additional information is available on the Company's website at:
www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 27E of the
Securities Act of 1934. Statements contained in this release that are not
historical facts may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected or suggested
herein due to certain risks and uncertainties including, without limitation,
ability to obtain financing and regulatory and shareholder approval for
anticipated actions.

SOURCE Solos Endoscopy, Inc.

Investor Relations for Solos Endoscopy, Inc., +1-866-843-2775